1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Where does Sobi fit: with Biogen or Baxter, Novo or Pfizer?

 
• By John Hodgson

Swedish Orphan Biovitrum (SOBI) has been approached by a mystery corporate buyer, the company confirmed on 27 April. But the company has given no indication where the approach comes from. The most likely acquirer is Biogen, SOBI's US and rest-of-world partner for two hemophilia products approved in the US. But Pfizer is also a long-term partner of SOBI's in hemophilia, and hemophilia market leader Baxter has been strengthening its offering through acquisition in recent years. Novo Nordisk might also be a decent fit, if it were not for Novo's reticence about growth based on acquisition.

Swedish Orphan Biovitrum (SOBI) has been approached by a mystery corporate buyer, the company confirmed on 27 April. But the company has given no indication where the approach comes from. The most likely acquirer is Biogen, SOBI's US and rest-of-world partner for two hemophilia products approved in the US. But Pfizer is also a long-term partner of SOBI's in hemophilia, and hemophilia market leader Baxter has been strengthening its offering through acquisition in recent years. Novo Nordisk might also be a decent fit, if it were not for Novo's reticence about growth based on acquisition.

2014 was not the best year for SOBI: it wrote off two important parts of its biopharmaceutical development portfolio: its...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

After Gilead Deal, Hookipa Hangs Up Its Hat

 
• By Kevin Grogan

The Austrian firm is delisting from the NASDAQ and closing down.

Genentech Gets Columvi Complete Response Following ODAC’s No

 
• By Joseph Haas

Seeking to move Columvi into second-line DLBCL, Genentech got an FDA letter saying the Phase III STARGLO study’s benefits may have been driven by results in Asian enrollees.

BMS’s Reblozyl Misses Primary Endpoint In Myelofibrosis Anemia

 
• By Alaric DeArment

The drugmaker announced topline results from the Phase III INDEPENDENCE trial, which did meet key secondary endpoints.

AI-First, Big Pharma, Chinese Firms In Race - What’s Ahead For PRMT5 Inhibitors

 
• By Vibha Ravi

As AI-driven firms including Insilico, big pharmas J&J, Amgen, GSK and AstraZeneca and Chinese and Indian firms like BeOne and Dr. Reddy’s advance PRMT5 inhibitor candidates, what’s driving interest, what could lead to the first global approval and what are the challenges ahead?

More from Therapy Areas

BMS’s Reblozyl Misses Primary Endpoint In Myelofibrosis Anemia

 
• By Alaric DeArment

The drugmaker announced topline results from the Phase III INDEPENDENCE trial, which did meet key secondary endpoints.

Insmed’s New R&D Site Focused On ‘Synthetic Rescue’

 
• By Andrew McConaghie

A new small-molecule approach to turning on beneficial genes to counteract disease-causing mutations is being pioneered by Insmed’s UK-based scientists.

AI-First, Big Pharma, Chinese Firms In Race - What’s Ahead For PRMT5 Inhibitors

 
• By Vibha Ravi

As AI-driven firms including Insilico, big pharmas J&J, Amgen, GSK and AstraZeneca and Chinese and Indian firms like BeOne and Dr. Reddy’s advance PRMT5 inhibitor candidates, what’s driving interest, what could lead to the first global approval and what are the challenges ahead?